Cancer Immunotherapy

Cancer immunotherapy helps your immune system to recognise and attack cancer. The most widely used type is the checkpoint inhibitor: antibody drugs such as pembrolizumab, nivolumab, atezolizumab and ipilimumab, which release the brakes that tumours use to switch off immune T cells. They are given as a drip every 2 to 6 weeks.

In some cancers, including melanoma, lung, kidney, bladder, head and neck cancers and tumours with mismatch repair deficiency, a proportion of patients have deep and long-lasting responses. Many patients do not respond at all, it is not yet possible to predict reliably who will, and side effects can be serious.

What Cancer Immunotherapy involves

Eligibility rests on the type and stage of the cancer and on biomarker tests of the tumour tissue, mainly PD-L1 expression, mismatch repair or microsatellite instability status and, in some cases, tumour mutational burden. Baseline blood tests check thyroid, liver, kidney and adrenal function. The drug is infused in a day unit over 30 to 60 minutes, alone or in combination with chemotherapy, a targeted drug or a second immunotherapy. Before each dose you have blood tests and a symptom review, because side effects are caused by the immune system attacking normal organs. Scans are repeated every 8 to 12 weeks. Treatment continues for a fixed period, often 1 to 2 years, or until the cancer progresses or side effects force a stop.

Who is a good candidate for Cancer Immunotherapy?

Immunotherapy is recommended only where trials have shown a benefit for that cancer and setting.

• Advanced melanoma, and as additional treatment after surgery for high-risk melanoma
• Non-small cell lung cancer, selected by PD-L1 level and the absence of certain driver mutations
• Kidney, bladder, head and neck, liver, oesophageal and stomach cancers in defined settings
• Any solid tumour with mismatch repair deficiency or high microsatellite instability
• Hodgkin lymphoma and some other lymphomas after earlier treatments
• Triple-negative breast cancer and cervical cancer with PD-L1 expression, in combination with chemotherapy

It is usually not the right choice if:

• Active autoimmune disease requiring strong immunosuppression, unless carefully weighed by specialists
• Organ transplant recipients, in whom rejection can be triggered
• Cancers and subtypes in which trials have shown no benefit, such as most microsatellite-stable bowel cancers and most prostate cancers
• People needing high-dose steroids for other reasons
• Anyone offered it outside approved uses on the basis of hope alone, without a frank discussion of the evidence

الخيارات التقنية

• PD-1 and PD-L1 inhibitors: The mainstay drugs, used alone or with chemotherapy.
• CTLA-4 inhibitors: Ipilimumab and tremelimumab, usually combined with a PD-1 drug; more effective in some cancers, at the price of more side effects.
• CAR-T cell therapy: Your own T cells are re-engineered in a laboratory. Approved for certain leukaemias, lymphomas and myeloma, in specialised centres only.
• Bispecific antibodies: Link T cells to cancer cells; used in some blood cancers and a few solid tumours.
• BCG and oncolytic virus therapy: Local immunotherapies for bladder cancer and for melanoma.
• Unproven immune boosting infusions: Vitamin drips, ozone, unlicensed cell infusions and the like, sold as immunotherapy by some clinics. These are not what oncologists mean by the term and should be avoided.

ماذا يحدث خلال علاجك

Each visit takes 1 to 3 hours in a day unit, including checks; the infusion itself lasts 30 to 60 minutes. Infusion reactions, such as flushing, chills or itching, are uncommon and are treated at once. Most people feel well on the day and go home soon afterwards.

الإعداد لرحلتك

Treatment is given every 2 to 6 weeks for up to 2 years, and side effects can appear at any point, even months after the last dose. It therefore needs an oncology team near where you live. A trip can reasonably cover biomarker testing on your tumour tissue, a second opinion on whether immunotherapy is suitable, and perhaps the first dose, with subsequent doses given at home.

• Tell the doctor about medication, allergies, pregnancy or breastfeeding, and any history of cold sores, keloid scars or autoimmune disease
• Avoid alcohol, aspirin and anti-inflammatory painkillers for a few days beforehand if your own doctor agrees, to reduce bruising
• Arrive without make-up on the treatment area and avoid sunbeds and strong sun for two weeks before

التعافي والنتائج

There is usually little immediate downtime, and most people go on with normal life between doses. Tiredness, an itchy rash and mild diarrhoea are the most common side effects. The essential point is to report any new symptom early, including diarrhoea, breathlessness, cough, severe tiredness, headache, yellow skin or a changed heartbeat, because immune side effects respond well to prompt steroid treatment and can become dangerous if ignored. The first scan may occasionally show apparent growth before shrinkage, known as pseudoprogression.

• Back to everyday activity: Usually little; varies with side effects
• When results show: First response scan at 8 to 12 weeks
• How long they last: Varies widely; responses can be long-lasting in a minority

سياسة السلامة والمخاطر والتنقيح

Side effects differ from those of chemotherapy: they are inflammatory and can involve any organ.

• Skin rash and itching
• Colitis with diarrhoea, which can be severe
• Thyroid, pituitary or adrenal gland inflammation, sometimes requiring lifelong hormone replacement
• Hepatitis shown on blood tests
• Pneumonitis, inflammation of the lungs causing cough and breathlessness
• Less often, inflammation of the heart, nerves, kidneys or joints, and new-onset type 1 diabetes
• A small risk of life-threatening reactions, higher with combination treatment
• No response, which remains the outcome for many patients

Every written proposal arranged through Clinic-Y states what the clinic covers if a correction is needed. Ask for it before you book, not after.

Cost of Cancer Immunotherapy in Türkiye

Clinic-Y does not publish a single price for Cancer Immunotherapy, because the honest figure depends on your case. What moves it:

• The drug, which is the dominant cost, and whether a combination is used
• Dosing interval and the total duration of treatment
• Biomarker testing of the tumour
• Monitoring blood tests and scans
• Treatment of side effects, including hospital admission

Send your photographs or reports and you receive written, all-inclusive proposals from suitable teams, side by side. Reviewing your case is free.

الأسئلة المتكررة